SLKDT intervention significantly inhibited obesity‐induced inflammation by decreasing the proinflammatory factors IL‐6, TNF‐α, IFN‐γ, and IL‐1β and increasing the anti‐inflammatory cytokines IL‐4 and IL‐10. Here, IL6 is linked to obesity disorder.